ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Spero Therapeutics Announces Proposed Offering of Common Stock
firstwordpharma
July 10, 2018Spero Therapeutics, Inc. (Nasdaq:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections -
Spero Therapeutics Receives Grant from NIH
americanpharmaceuticalreview
May 05, 2017Spero Therapeutics announced it has received a grant from the National Institutes of Health (NIH) to conduct additional preclinical studies of SPR720, the company's novel oral bacterial gyrase inhibitor, for the treatment of tuberculosis (TB).
Pharma Sources Insight January 2025
